Investment
Bezos Expeditions participated as a new investor in LifeMine Therapeutics' combined $263M Series D/E fundraising. LifeMine develops precision medicines sourced from fungal genomics for organ transplant aftercare, with lead asset LIFE-001 in Phase 1 trials.
LifeMine Therapeutics
AUG 6, 2026